Skip to main content
To reduce proteinuria in adults with primary IgAN at risk of rapid disease progression (generally a UPCR ≥1.5 g/g). Explore a different path for their IgAN.

Target the alternative complement pathway1

See how FABHALTA works

See trial results for FABHALTA

Explore the safety profile for FABHALTA

Download the Start Form

Definitions
IgAN, immunoglobulin A nephropathy; MOA, mechanism of action; UPCR, urine protein-to-creatinine ratio.

Reference
1. Fabhalta. Prescribing information. Novartis Pharmaceuticals Corp.